Efzofitimod’s path to a pivotal trial just cleared a meaningful bureaucratic hurdle: aTyr Pharma has reached agreement with the FDA on the protocol for a Phase 3 study in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. Protocol alignment with regulators before a Phase 3 opens is not guaranteed, and getting there before study initiation removes a common source of mid-trial disruption.
The company plans to file regulatory submissions in both the U.S. and Europe as it begins study-related activities in the fourth quarter of 2026. That parallel submission strategy suggests aTyr intends to run a globally enrolled trial rather than a U.S.-only program, which would expand the patient pool and, if the drug succeeds, position it for simultaneous review on both sides of the Atlantic. Pulmonary sarcoidosis with restrictive lung disease is a condition where approved options remain largely limited to corticosteroids and repository corticotropin injection, leaving patients with progressive disease and few alternatives.
The Phase 3 builds on a randomized, double-blind, placebo-controlled Phase 1b/2a study in 37 pulmonary sarcoidosis patients that showed dose-dependent improvements across several clinical endpoints, with the drug well tolerated across the dose range tested. A 37-patient study is small, so the Phase 3 will need to demonstrate whether those signals hold in a larger, more representative population. Protocol-level FDA alignment is one signal that the agency found the earlier data sufficient to define a testable hypothesis, though the filing does not specify what endpoints or patient selection criteria the two sides agreed on.
The concrete marker to track now is whether aTyr completes its IND and EU CTA submissions on the fourth-quarter timeline it has set. Any slip in those filings delays site activation, and site activation is where agreements on protocol design actually get stress-tested.
Source link: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000065/atyr-20260924.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
